Everand Logo

Welcome to Everand!

  • STAT

    Opinion: We must improve the security of networked medical devices

    Instead of waiting for networked medical devices to be compromised, the industry needs to understand their security risks and take steps to protect them.
    by Alexander P. Cole and M. Carlton and Quoc-Dien Trinh Nov 02, 2017 4 minutes
    Networked "smart" devices, like surgical robots, are poised to revolutionize health care. But with these new opportunities come new risks.

    Networked “smart” devices are poised to revolutionize health care, from infusion pumps that provide essential safety checks for the medications they deliver to multimillion-dollar robots that allow for more precise surgery and Bluetooth-connected pacemakers. But with these new opportunities come new risks — especially in a vulnerable setting such as a hospital.

    This was brought to the fore last spring when the WannaCry ransomware attack roiled the British National Health Service, going so far as to disable CT and MRI machines used for crucial diagnostic procedures. Another ransomware attack, called Bad Rabbit, recently started spreading around Eastern Europe with the potential for similar damage.

    Physicians are often quick to embrace the latest high-tech

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks